Study of Probiotic GanedenBC30 for Irritable Bowel Syndrome and Major Depressive Disorder
Status:
Terminated
Trial end date:
2012-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety and effectiveness of a nutritional
supplement, the probiotic bacteria GanedenBC30. Probiotics are live microorganisms which when
taken in large enough amounts are supposed to provide a health benefit. The investigators
would like to see whether this supplement can be used as a treatment for Irritable Bowel
Syndrome (IBS) and Major Depressive Disorder (MDD). Participants in the study will have both
IBS and MDD. In order to find out if GanedenBC30 is effective in treating IBS and MDD, the
investigators will compare it to a placebo. About 32 people will take part in this research
study. About half of these 32 people will take part at Charles River Medical Associates and
half will take part at Burlington Medical Associates. Participants will be recruited from
among patients already being seen at Charles River Medical Associates or Burlington Medical
Associates for their primary care. The study will last for two months, during which time
participants will make eight study visits and will take either Ganeden BC30 or placebo. The
investigators hypothesize that subjects treated with the probiotic will have significantly
better outcomes with regard to depression and IBS symptoms compared to those who receive
placebo.